Previous 10 | Next 10 |
NEW YORK, NY, April 20, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) recently entered into a licensing agreement with Hai Kang Life Corporation (Hai Kang), where Hai Kang granted to PharmaCyte a license to the technology related to its COVID-19 diagnostic testing kits. Th...
NEW YORK, NY, April 13, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) is a California-based biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , and while it continue...
PharmaCyte Biotech ( OTCQB:PMCB +4.1% ) has entered into a license agreement with Hai Kang Life, for sharing certain technology owned or controlled by Hai Kang related to COVID-19 diagnostic kits. More news on: PharmaCyte Biotech, Inc., Healthcare stocks news, Read more ...
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it entered into a License Agreement (Agreement) with Hai Kang Li...
NEW YORK, NY, March 26, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) continues to work with consultants to prepare its Investigational New Drug application (IND). At the same time, PharmaCyte is reportedly completing the remaining tests that will provide the last major pi...
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today the latest in its series of Q&A articles that are conducted with ...
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has received the Certificates of Analysis and the records fro...
New York, New York--(Newsfile Corp. - February 11, 2020) - Investors searching for emerging leaders in the cellular therapeutics sector may find interest in PharmaCyte Biotech, a company committed to its development of cancer and diabetes treatments that have the potential to revolutionize the...
Miami Beach, Florida--(Newsfile Corp. - February 6, 2020) - For investors interested in finding undervalued opportunity, PharmaCyte Biotech may be a stock to watch as the company positions itself to potentially create enormous shareholder from its ongoing development of cellular therapies targ...
NEW YORK, NY, Feb. 04, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) is about to embark upon a planned U.S. FDA Phase 2b clinical trial to treat locally advanced, inoperable pancreatic cancer (LAPC) at trial sites all over the United States, and with that journey comes the need ...
News, Short Squeeze, Breakout and More Instantly...
PharmaCyte Biotech Inc. Company Name:
PMCB Stock Symbol:
OTCMKTS Market:
PharmaCyte Biotech Inc. Website:
Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”), today announced a $7 mi...